Objective: To assess the role of noninvasive ventilation in the treatment of children with acute respiratory failure. Methods: A systematic review of literature on noninvasive ventilation in MEDLINE, LILACS, EMBASE, and Cochrane databases, besides references in articles. The outcomes evaluated were responses in blood oxygenation and ventilation, and patient survival. Results: A total of 120 studies on noninvasive ventilation were found as of May, 2010. Of these, only 19 were about noninvasive ventilation in children. On the other hand, there are prospective and cohort clinical trials leading to a level II quality of evidence concerning the use of noninvasive ventilation in children. Conclusion: There is scientific evidence for proposing the use of noninvasive ventilation, with a B-II degree of recommendation. 
INTRODUCTION
Among the diseases that place at risk the life of a pediatric patient, and especially, its future quality of life, acute respiratory failure (ARF) is one of the most important. A child's respiratory system has several particularities that facilitate the development of respiratory insufficiency. In addition, respiratory diseases occur frequently in the pediatric age range.
The use of invasive mechanical ventilation allows a more adequate treatment of patients with ARF; but positive pressure in the patients' airways acts inversely to normal respiratory physiology. This may result in complications due to lack of pressure. Additionally, the intubation procedure and the presence of the cannula in the airway may promote local lesions and predispose to pulmonary infections.
As an alternative to tracheal intubation, noninvasive ventilation (NIV) is a technique in which positive pressure is applied to the patient's airway by means of masks or interfaces without tracheal cannulation.
The use of NIV in selected groups of adult patients, such as those with acute exacerbation of chronic obstructive pulmonary disease (COPD), reduces the need for intubation, mortality, and costs of treatment (1) . In 1987, the first use of NIV with a nasal mask was recorded in a six-year-old child with a primary diagnosis of alveolar hyperventilation (2) . Over the last 20 years, the number of experiences with the use of NIV in children has been increasing.
OBJECTIVE
To discuss the accumulated experience on NIV in clinical trials with the purpose of evaluating its role in the treatment of ARF in pediatric patients.
METHODS

Identification of studies
The bibliographical survey was made systematically, seeking publications in Portuguese, English, and Spanish. The following databases were used, from the onset to May, 2010: MEDLINE (as of 1966); LILACS (as of 1983); EMBASE (as of 1974); Cochrane Library (as of 1993). Also used were the references cited in reviews and articles.
The terms used for the investigation were "noninvasive ventilation;" "acute respiratory failure;" "BIPAP;" "CPAP;" "hypoxemia;" "hypercapnia."
Selection criteria
The following criteria were considered for study selection:
A. Study design • Randomized clinical trials.
• Case series.
• Systematic reviews.
B. Population
Children and adolescents up to 18 years of age with ARF. C. Exclusion criteria (3) .
RESULTS
Systemic search in publications
One hundred and twenty studies on NIV were found during the study period. Of these, only 19 satisfied the established selection criteria, and they are shown on Chart 1.
In a systematic review of NIV with negative pressure, only one study, in which 33 children with bronchiolitis were studied, was considered eligible. The experimental group treated with negative pressure NIV displayed a reduced need for oxygen in one hour and none of the children in this group required CPAP or invasive mechanical ventilation. The authors concluded that there was information lacking and that controlled
Stregth of recommendation
Quality of evidence A. Good evidence supporting recommendation for use 1. Evidence of at least one appropriate randomized controlled trial, B. Moderate evidence supporting the recommendation of use 2. Evidence of at least one well designed trial, not randomized; of cohort or case-control studies (preferably from more than one center); of several temporal series or of significant results of non-controleed trials C. Weal evidence supporting recommendation 3. Evidence of experts in the subject, based on clinical experience, descriptive studies or reports of experts D. Moderate evidence supporting against recommendation of use E. Good evidence supporting against recommendation of use studies would be necessary which could support the use of negative pressure NIV in children with ARF (9) . The first crossover randomized clinical trial assessed the effects of NIV in 16 children with obstruction of the lower airways, characterized by increased breathing work and dyspnea, using the Clinical Asthma Score (CAS). Patients were randomized to two groups: Group 1, which received NIV in addition to conventional treatment (high flow oxygen, inhalation with bronchodilator, and corticoids) for two hours; and Group 2, which during the first two hours received only conventional treatment. After two hours, treatment between the groups was inverted (crossover): Group 1 began to receive only conventional treatment and Group 2 received NIV in addition to conventional treatment. There was significant improvement in respiratory rate (p < 0.0001) and CAS (p < 0.0001) in the NIV group (10) . In the study by Villanueva, the effects of NIV were evaluated in 23 patients with hypoxemic respiratory insufficiency, hypercapnia, or postextubation respiratory insufficiency. After the start of NIV, there was significant improvement of the respiratory rate (p < 0.001), heart rate (p = 0.001), and of the PaO2/FiO2 ratio (p=0.010). Of the 23 patients who received NIV, five required intubation and invasive mechanical ventilation (12) . At a single center, 15 children aged one month to five years with hypoxemic respiratory insufficiency were evaluated. NIV was performed with additional sedation, when necessary, and the mask was well tolerated by all patients. Of the 15 children, 10 had multiple organ dysfunction and 9 were under one year of age. None of them experienced complications. Oxygenation improved after two hours of NIV, and no hemodynamic variation was detected (21) . The efficacy of NIV was evaluated in an Italian Intensive Care Unit (ICU) with 24 beds, during two years, analyzing pH, CO2, SatO2, respiratory rate, and need for oxygen. Twenty patients with a mean age of 7.4 years (± 0.28 years), with ARF, received NIV, and for the analysis they were divided into two groups:
Author Study (n) Year of publication Population Akingbola et al. (4) Case report (2) 1993 Children with atelectasis Fortenberry et al. (5) Case series (28) 1995 Children with ARF Padman et al. (6) Case series (34) 1998 Patients aged between 6 months and 18 years with ARF Sprague et al. (7) Case series (5) 2000 Patients aged between 12 years and 18 years with ARF secondary to cystic fibrosis Akingbola et al. (8) Case report (3) 2002 Children with asthma and hypercapnia Shah et al. (9) Systematic review 2003 Children with bronchiolitis in ARF Thill et al. (10) Randomized crossover clinical trial (16) 2004 Children with lower airways obstruction Piastra et al. (11) Case series (4) 2004 Children aged between 9 and 17 years with acute leukemia and hypoxemic ARF Villanueva et al. (12) Case series (23) 2005 Hypoxemic and hypercapnic ARF or respiratory failure after extubation Chin et al. (13) Case series (15) 2005 Children aged 5 months and 14 years, submitted to liver transplant, that progressed with ARF and atelectasis Prado et al. (14) Case series (14) 2005 Children aged between 1 month and 13 years, with ARF, reduced oxygenation (saturation < 93% with FiO2 > 40%) and ventilation (pH < 7,25), besides radiological impairment Carroll e Schramm (15) Case series (5) 2006 Children aged between 2 years and 18 years, with acute asthma, hypoxemia and increased respiratory work Essouri et al. (16) Retrospective cohort (114 (20) Retrospective study 2007 Twenty patients with mean ages of 7.4 years, with ARF, received NIV and were divided into two groups for analysis: hypoxic and hypercapneic group. Codazzi et al. (21) Case series (15) 2006 Fifteen children from 1 month to 5 years with hypoxemic ARF Piastra et al. hypoxic group and hypercapnic group. Of these 20 patients, 15 displayed an improvement in oxygenation and ventilation; five required invasive mechanical ventilation; and two experienced pressure ulcers on nasal bridges, which were rapidly reversible (20) . Essouri et al. (16) carried out a retrospective cohort study with patients aged 15 to 17 years treated with NIV for two hours or more, between January 1 st , 2000, and December 31 st , 2004. Included were 114 patients, and of these, 83 (77%) were successfully treated with NIV, with no intubation. The success of NIV use was significantly lower (22%) in the group with acute respiratory distress syndrome (ARDS). PRISM II and the Pediatric Logistic Organ Dysfunction (PELOD) at admission were clearly higher in patients who did not have success with NIV. In the group of responders to NIV, there was a distinct drop in respiratory rate and PCO2 within the first two hours of NIV. A multivariate analysis showed that the diagnosis of ARDS and the high value of PELOD were predictive factors for treatment failure with NIV.
Yañez et al. (17) conducted a controlled randomized prospective multicentric study in Santiago, Chile. Fifty patients with ARF were studied; 25 received NIV and 25 received conventional treatment with medication, inhalation, and O2 nebulization. Comparing the values to those of admission, the PaO2/FiO2 ratio and cardiac and breathing rates after our hour of treatment improved significantly in the group that received NIV. The improvement continued to be observed over time, with a drop in heart rate after six hours of therapy. Use of intubation was 28% lower in the group that received NIV relative to controls.
Essouri et al. (18) published a second study in 2008, which was prospective, carried out from December 2004 to January 2007. Patients from one to 18 years of age were evaluated who weighed more than 10 kg, admitted to the ICU with moderate hypercapnic respiratory insufficiency (defined by respiratory rate equal to or greater than the 97 th percentile for the age group, associated with PCO2 ≥ 40 mmHg). Only patients treated with NIV for less than 12 hours were included. NIV was associated with an improvement in the breathing pattern, better gas exchange, and less use of accessory muscles. The improvement in alveolar ventilation was translated as a partial reduction in PCO2 from 48 to 40 mmHg, and in a respiratory rate between 48 and 41.
A national retrospective cohort study evaluated children admitted to the ICU at the Cancer Hospital between June 1997 and May 2005. Included were 239 patients: 120 of them received NIV as the first technique for ventilation and 119 received conventional mechanical ventilation. Of the patients submitted to NIV, 25.8% required intubation. The groups were not paired, and the patients who received invasive mechanical ventilation were in more serious clinical condition. The values of arterial PCO2, hypoxemia, arterial pH, and respiratory rate were no different between the two groups. The study results encourage the use of NIV as the first treatment in oncologic children with respiratory insufficiency, and without hemodynamic instability (19) . Piastra et al. (22) developed a prospective cohort study with 23 immunocompromised patients with ARDS admitted to the ICU of a university hospital and treated with NIV. There was no difference in the scores of severity between the NIV responders and non-responders. The improvement in the PaO2/ FiO2 ratio was significant and precocious. Of the 23 patients, 13 were able to avoid intubation and were discharged from the ICU. Ten required intubation, and of these, two survived and eight died (two due to refractory hypoxemia, three due to septic shock, and three due to multiple organ failure). The mortality of non-responders to NIV was high both in the ICU and in the hospital, in general. ICU stay was shorted for those responsive to NIV, who also showed an improvement in heart and respiratory rates at the end of the treatment. It was concluded that NIV is well tolerated and feasible in children immunocompromised with ARDS, but a randomized controlled study is necessary to confirm the efficacy of this method.
DISCUSSION
The clinical evaluation of the benefits of NIV was performed by means of a randomized clinical trial with the general pediatric population (17) and a trial in the subpopulation with asthma (10) . Such studies were not completely appropriate since they did not compare NIV with the invasive treatment, but with conventional treatment.
The other studies included in this review showed clinical improvement in children and adolescents treated with NIV. With ventilatory support provided via masks, the patients showed reduced respiratory discomfort, in addition to improved oxygenation and ventilation, assessed by arterial gasometry or by noninvasive monitoring methods, such as pulse oximetry.
Controlled studies in adults demonstrated similar results: reduction in respiratory rate, reduction in respiratory discomfort, and improvement in oxygenation (23, 24) . The studies carried out by Essouri et al. (16, 18) and Ottonello et al. (20) allow rating and recommendation of use of NIV at the B-II level.
NIV proved particularly feasible in oncologic patients (19, 22) .
CONCLUSION
There is currently scientific evidence to recommend the routine use of NIV, with a B-II degree of recommendation, due to the reduced number of controlled and randomized studies. The articles published to date suggest beneficial physiological effects. New randomized studies with larger numbers of cases to better define the role of NIV in treating respiratory insufficiency in the pediatric population are welcome.
